Haemonetics Corporation announced today that Christopher Lindop, Chief Financial Officer and Executive Vice President, Business Development has announced his retirement from Haemonetics Corporation effective May 27, 2016. The Company announced it will immediately begin a search for Mr. Lindop’s successor.
Mr. Lindop joined the Company in 2007 and has led the Company’s finance, investor relations and business development activities.
“Chris has made significant contributions to our global business and we wish him the best on his well-deserved retirement,” said Ron Gelbman, Interim CEO.
Source: Haemonetics
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.
